Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00264576 · ClinicalTrials.gov registry record · Phase 2
Study of the Safety and Immunogenicity of an Influenza Vaccine Administered to Healthy Adults
A Phase 2 study, sponsored by Novartis Vaccines.
- Completed
- Registry status
- Phase 2
- Development phase
- 613
- Enrollment target
NCT00264576 is a Phase 2 study that has completed, run by Novartis Vaccines. The registered enrollment target is 613 participants.
The verdict
NCT00264576, a Phase 2 study, has completed, sponsored by Novartis Vaccines.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 613 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and immunogenicity of cell culture-derived, inactivated, subunit influenza vaccine in comparison to licensed Fluvirin vaccine administered to healthy adults ages 18 \< 50 years.
Interventions
- BIOLOGICAL Influenza Virus Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 613 participants |
| Start Date | 2005-10 |
| Est. Completion | 2006-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00264576
The ClinicalTrials.gov registry entry for NCT00264576 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 613 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Vaccines, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Influenza Virus Vaccine is the first listed.
NCT00264576 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00264576 about?
NCT00264576 is a clinical study titled "Study of the Safety and Immunogenicity of an Influenza Vaccine Administered to Healthy Adults". The purpose of this study is to evaluate the safety and immunogenicity of cell culture-derived, inactivated, subunit influenza vaccine in comparison to licensed Fluvirin vaccine administered to healthy adults ages 18 \< 50 years.
What is the current status of trial NCT00264576?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 613 participants. The study started on 2005-10. Estimated completion is 2006-05.
What interventions are being tested in trial NCT00264576?
The interventions under investigation include: Influenza Virus Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00264576?
This trial is sponsored by Novartis Vaccines, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.